1932

Abstract

Molecular diagnostic tests enable rapid analysis of genomic and proteomic markers. These tests are subject to diverging premarket access and postmarket surveillance requirements and mechanisms in the United States and the European Union. Each of these jurisdictions has its own challenges in keeping the regulations up to date with technological developments. A specific area of attention is that of laboratory-developed tests in the United States and health institution in-house-produced tests in the European Union, for which the United States and the European Union have markedly different regulatory approaches. Both jurisdictions have specific but differing requirements for the use of test samples and test-related data under their rules regarding the protection of (personal) health data, which can cause complexity when moving samples or sample-related data from one jurisdiction to the other.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-genom-121521-010416
2022-08-31
2024-06-17
Loading full text...

Full text loading...

/deliver/fulltext/genom/23/1/annurev-genom-121521-010416.html?itemId=/content/journals/10.1146/annurev-genom-121521-010416&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Bath C. 2016. The FDA urges physicians and patients to forgo ovarian cancer screening tests. ASCO Post Oct. 10. https://www.ascopost.com/issues/october-10-2016/the-fda-urges-physicians-and-patients-to-forgo-ovarian-cancer-screening-tests
    [Google Scholar]
  2. 2.
    Brennan Z. 2018. FDA warns against use of unapproved genetic tests. Regulatory Focus Nov. 1. https://www.raps.org/news-and-articles/news-articles/2018/11/fda-warns-against-use-of-unapproved-genetic-tests
    [Google Scholar]
  3. 3.
    Cent. Medicare Medicaid Serv. 2014. Research testing and Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations. Centers for Medicare and Medicaid Services https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/research-testing-and-clia.pdf
    [Google Scholar]
  4. 4.
    Cent. Medicare Medicaid Serv. 2021. Clinical laboratories. Centers for Medicare and Medicaid Services https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/Certificationand-Complianc/Labs
    [Google Scholar]
  5. 5.
    Cent. Medicare Medicaid Serv. 2021. Laboratory registry. Centers for Medicare and Medicaid Services https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Laboratory_Registry
    [Google Scholar]
  6. 6.
    Cent. Medicare Medicaid Serv. 2021. List of approved accreditation organizations under the Clinical Laboratory Improvement Amendments (CLIA). Centers for Medicare and Medicaid Services https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/AOList.pdf
    [Google Scholar]
  7. 7.
    Charrow R. 2020. Memorandum from Robert Charrow, General Counsel, US Department of Health and Human Services, to Stephen Hahn, M.D., Commissioner of Food and Drugs. Memo., June 22 US Dep. Health Hum. Serv. Washington, DC: https://www.thefdalawblog.com/wp-content/uploads/2021/11/HHS-Legal-Memo-on-LDTs-by-Charrow-00864663.pdf
    [Google Scholar]
  8. 8.
    Cobbaert C, Capoluongo ED, Vanstapel FJLA, Bossuyt PM, Bhattoa HP et al. 2022. Implementation of the new EU IVD regulation – urgent initiatives are needed to avert impending crisis. Clin. Chem. Lab. Med. 60:33–43
    [Google Scholar]
  9. 9.
    Coll. Am. Pathol. 2021. CAP accreditation checklists – 2021 edition. College of American Pathologists. https://documents.cap.org/documents/cap-accreditation-checklists.pdf
    [Google Scholar]
  10. 10.
    Eur. Comm. 2016. Commission notice: the ‘Blue Guide’ on the implementation of EU products rules 2016 O.J. C 272/1
    [Google Scholar]
  11. 11.
    Eur. Comm. 2022. Ongoing guidance development and deliverables of MDCG Subgroups – May 2022. European Commission https://ec.europa.eu/health/sites/default/files/md_sector/docs/mdcg_ongoing_guidancedocs_en.pdf
    [Google Scholar]
  12. 12.
    Eur. Comm. 2021. Proposal for a regulation of the European Parliament and of the Council amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and deferred application of requirements for in-house devices COM(2021) 627, 2021/0323 (COD) Eur. Comm. Brussels:
    [Google Scholar]
  13. 13.
    Eur. Parliam. 1998. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices O.J. L 331/1
    [Google Scholar]
  14. 14.
    Eur. Parliam. 2016. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) O.J. L 119/1
    [Google Scholar]
  15. 15.
    Eur. Parliam. 2017. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC O.J. 2017 L117/1
    [Google Scholar]
  16. 16.
    Eur. Parliam. 2017. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU O.J. L 117/176
    [Google Scholar]
  17. 17.
    Eur. Parliam. 2019. Regulation (EU) 1020/2019 of the European Parliament and of the Council of 20 June 2019 on market surveillance and compliance of products and amending Directive 2004/42/EC and Regulations (EC) No 765/2008 and (EU) No 305/2011 O.J. L 169/1
    [Google Scholar]
  18. 18.
    Eur. Parliam. 2022. Regulation (EU) 2022/112 of the European Parliament and of the Council of 25 January 2022 amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and the deferred application of conditions for in-house devices O.J. L 19/3
    [Google Scholar]
  19. 19.
    Evans BJ, Javitt GH, Hall R, Robertson M, Ossorio P et al. 2020. How can law and policy advance quality in genomic analysis and interpretation for clinical care?. J. Law Med. Ethics 48:44–68
    [Google Scholar]
  20. 20.
    Gibbs JN. 2020. Introduction. . See Ref. 22, pp. vii–xii
  21. 21.
    Gibbs JN, Javitt GH. 2021. A VALID argument: Proposed legislation would reshape regulation of diagnostics. FDA Law Blog July 9. https://www.thefdalawblog.com/2021/07/a-valid-argument-proposed-legislation-would-reshape-regulation-of-diagnostics
    [Google Scholar]
  22. 22.
    Gibbs JN, Mullen AB, eds. 2020. Diagnostics at a Crossroads: Navigating IVD Regulation in a Changing Environment Washington, DC: Food Drug Law Inst.
    [Google Scholar]
  23. 23.
    Gutierrez A. 2010. Warning letter to 23 and Me, Inc. Lett., June 10 US Food Drug Adm. Silver Spring, MD: https://www.fda.gov/media/79205/download
    [Google Scholar]
  24. 24.
    Gutman S. 2007. Warning letter to EXACT Sciences Corporation Lett., Oct. 11 US Food Drug Adm. Silver Spring, MD: https://www.fdalabelcompliance.com/letters/ucm076536
    [Google Scholar]
  25. 25.
    Gutman S. 2008. Warning letter to Laboratory Corporation of America Lett., Sept. 29 US Food Drug Adm. Silver Spring, MD: https://www.fdalabelcompliance.com/letters/ucm1048114
    [Google Scholar]
  26. 26.
    Heger M. 2012. CAP publishes accreditation checklist for NGS in clinical labs. GenomeWeb Aug. 2. https://www.genomeweb.com/sequencing/cap-publishes-accreditation-checklist-ngs-clinical-labs
    [Google Scholar]
  27. 27.
    Int. Med. Device Regul. Forum. 2013. Software as a medical device (SaMD): key definitions Doc. IMDRF/SaMD WG/N10FINAL:2013 Int. Med. Device Regul. Forum. https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-131209-samd-key-definitions-140901.pdf
    [Google Scholar]
  28. 28.
    Int. Med. Device Regul. Forum. 2018. Essential principles of safety and performance of medical devices and IVD medical devices Doc. IMDRF/GRRP WG/N47 FINAL:2018 Int. Med. Device Regul. Forum https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-181031-grrp-essential-principles-n47.pdf
    [Google Scholar]
  29. 29.
    Int. Med. Device Regul. Forum. 2021. About IMDRF. International Medical Device Regulators Forum. http://www.imdrf.org/about/about.asp
    [Google Scholar]
  30. 30.
    Int. Med. Device Regul. Forum. 2021. Home page. International Medical Device Regulators Forum http://www.imdrf.org
    [Google Scholar]
  31. 31.
    Int. Med. Device Regul. Forum. 2021. Principles of in vitro diagnostic (IVD) medical devices classification Doc. IMDRF/IVD WG/N64FINAL:2021 Int. Med. Device Regul. Forum http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-wng64.pdf
    [Google Scholar]
  32. 32.
    Javitt GH. 2020. FDA regulation of LDTs. . See Ref. 22, pp. 135–48
  33. 33.
    Javitt GH, Gibbs JN. 2020. HHS reverses its position and no longer requires EUAs for COVID-19 LDTs. FDA Law Blog Aug. 20. https://www.thefdalawblog.com/2020/08/hhs-reverses-its-position-and-no-longer-requires-euas-for-covid-19-ldts
    [Google Scholar]
  34. 34.
    Javitt GH, Gibbs JN, Lewis RA, Cato ME. 2020. FDA, testing, and COVID-19: a “mid-mortem.”. FDA Law Blog Aug. 25. https://www.thefdalawblog.com/2020/08/fda-testing-and-covid-19-a-mid-mortem
    [Google Scholar]
  35. 35.
    Mazer R. 2020. Court finds CLIA violations can lead to false claims act liability – decision could significantly impact CLIA compliance issues. LinkedIn Aug. 7. https://www.linkedin.com/pulse/court-finds-clia-violations-can-lead-false-claims-act-robert-mazer
    [Google Scholar]
  36. 36.
    Med. Device Coord. Group. 2021. Joint implementation and preparedness plan for Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) Doc., Med. Device Coord. Group https://ec.europa.eu/health/sites/default/files/md_sector/docs/md_joint-impl-plan_en.pdf
    [Google Scholar]
  37. 37.
    Mullen AB, Gibbs JN, Javitt GH. 2021. HHS revokes Trump-administration LDT policy. FDA Law Blog Nov. 29. https://www.thefdalawblog.com/2021/11/hhs-revokes-trump-administration-ldt-policy
    [Google Scholar]
  38. 38.
    Natl. Conf. State Legis. 2021. State genetic privacy laws. National Conference of State Legislatures http://pierce.wesleyancollege.edu/faculty/hboettger-tong/docs/hbt%20public%20folder/FYS/State%20Genetic%20Summary%20Table%20on%20Privacy%20Laws.htm
    [Google Scholar]
  39. 39.
    Natl. Inst. Health. 2004. Research repositories, databases, and the HIPAA Privacy Rule. National Institutes of Health https://privacyruleandresearch.nih.gov/research_repositories.asp
    [Google Scholar]
  40. 40.
    Norden M, Rosecrans H, Schultz D. 2020. Trying to fit a square peg into a round hole: perspectives on the regulation of in vitro diagnostic devices at the Center for Devices and Radiological Health. . See Ref. 22, pp. 1–10
  41. 41.
    Shapiro JK. 2021. Modernizing the regulation of laboratory developed tests (LDTs): Senator Rand Paul identifies a better way forward. FDA Law Blog June 14. https://www.thefdalawblog.com/2021/06/modernizing-the-regulation-of-laboratory-developed-tests-ldts-senator-rand-paul-identifies-a-better-way-forward
    [Google Scholar]
  42. 42.
    Shuren J 2015. Statement of Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health, Food and Drug Administration, Department of Health and Human Services, before the Subcommittee on Health, Committee on Energy and Commerce, U.S. House of Representatives. Statement, US House Represent. Washington, DC: https://docs.house.gov/meetings/IF/IF14/20151117/104127/HMTG-114-IF14-Wstate-ShurenJ-20151117.pdf
    [Google Scholar]
  43. 43.
    Stenzel T. 2019. Warning letter to Inova Genomics Laboratory Lett., Apr. 4 US Food Drug Adm. Silver Spring, MD: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/inova-genomics-laboratory-577422-04042019
    [Google Scholar]
  44. 44.
    Stenzel T. 2021. Warning letter to Lepu Medical Technology -Beijing- Co., Ltd Lett., July 29 US Food Drug Adm. Silver Spring, MD: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lepu-medical-technology-beijing-co-ltd-614908-07292021
    [Google Scholar]
  45. 45.
    United States ex rel. Holland v. DaVita, Inc. Case 6:17-cv-1592-Orl-37GJK (M.D. Fla., June 24 2020. https://casetext.com/case/united-states-ex-rel-holland-v-davita-inc
    [Google Scholar]
  46. 46.
    US Dep. Health Hum. Serv. 2013. Summary of the HIPAA Privacy Rule. US Department of Health and Human Services https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations
    [Google Scholar]
  47. 47.
    US Dep. Health Hum. Serv. 2013. Summary of the HIPAA Security Rule. US Department of Health and Human Services https://www.hhs.gov/hipaa/for-professionals/security/laws-regulations
    [Google Scholar]
  48. 48.
    US Dep. Health Hum. Serv. 2017. Covered entities and business associates. US Department of Health and Human Services https://www.hhs.gov/hipaa/for-professionals/covered-entities/index.html
    [Google Scholar]
  49. 49.
    US Food Drug Adm. 2014. Citizen petition denial response from FDA CDRH to American Clinical Laboratory Association Lett., July 31 US Food Drug Adm. Silver Spring, MD: https://www.regulations.gov/document/FDA-2013-P-0667-0008
    [Google Scholar]
  50. 50.
    US Food Drug Adm. 2017. Software as a Medical Device (SAMD): clinical evaluation: guidance for industry and Food and Drug Administration staff Doc., US Food Drug Adm. Silver Spring, MD: https://www.fda.gov/files/medical%20devices/published/Software-as-a-Medical-Device-%28SAMD%29--Clinical-Evaluation---Guidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf
    [Google Scholar]
  51. 51.
    US Food Drug Adm. 2018. General controls for medical devices. US Food and Drug Administration. https://www.fda.gov/medical-devices/regulatory-controls/general-controls-medical-devices
    [Google Scholar]
  52. 52.
    US Food Drug Adm. 2018. Software as a Medical Device (SaMD). US Food and Drug Administration. https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd
    [Google Scholar]
  53. 53.
    US Food Drug Adm. 2019. Changes to existing medical software policies resulting from section 3060 of the 21st Century Cures Act, guidance for industry and Food and Drug Administration staff Doc. US Food Drug Adm. Silver Spring, MD: https://www.fda.gov/media/109622/download
    [Google Scholar]
  54. 54.
    US Food Drug Adm. 2019. Clinical decision support software: draft guidance for industry and Food and Drug Administration staff Doc., US Food Drug Adm. Silver Spring, MD: https://www.fda.gov/media/109618/download
    [Google Scholar]
  55. 55.
    US Food Drug Adm. 2021. 510(k) clearances. US Food and Drug Administration. https://www.fda.gov/medical-devices/device-approvals-denials-and-clearances/510k-clearances
    [Google Scholar]
  56. 56.
    US Food Drug Adm. 2021. Content of premarket submissions for device software functions: draft guidance for industry and Food and Drug Administration staff Doc. US Food Drug Adm. Silver Spring, MD: https://www.fda.gov/media/153781/download
    [Google Scholar]
  57. 57.
    US Food Drug Adm. 2022. Investigations operations manual Manual, US Food Drug Adm. Silver Spring, MD: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/investigations-operations-manual
    [Google Scholar]
  58. 58.
    US Food Drug Adm. 2021. Medical device de novo classification process 86 Fed. Reg. 54826. https://www.govinfo.gov/content/pkg/FR-2021-10-05/pdf/2021-21677.pdf
    [Google Scholar]
  59. 59.
    US Food Drug Adm. 2021. Regulatory procedures manual. Manual, US Food Drug Adm Silver Spring, MD: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-manuals/regulatory-procedures-manual
    [Google Scholar]
  60. 60.
    Vollebregt ER. 2021. Proposal to manage IVDR. Medical Devices Legal and Regulatory Blog Oct. 15. https://medicaldeviceslegal.com/2021/10/15/proposal-to-manage-ivdr
    [Google Scholar]
  61. 61.
    Wadsworth Cent. 2022. Clinical Laboratory Evaluation Program: a guide to program requirements and services Guide, Wadsworth Cent., N.Y. State Dep. Health Albany, NY: https://www.wadsworth.org/sites/default/files/WebDoc/CLEP_Program_Guide.pdf
    [Google Scholar]
/content/journals/10.1146/annurev-genom-121521-010416
Loading
/content/journals/10.1146/annurev-genom-121521-010416
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error